Various kinds of nonsteroidal anti-inflammatory drugs (NSAIDs) have been used in animals and human beings as analgesic agents for pain management in the treatment of orthopedic diseases, including osteoarthritis and fracture. Therapeutic effects of NSAIDs can be evoked by inhibiting the enzyme activity of cyclooxygenase (COX), resulting in decreased synthesis of inducible prostaglandin (PG) E~2~, which is one of key mediators of inflammation and a stimulator of pain-sensitizing neurons \[[@r14], [@r28]\]. However, the effects of NSAIDs on the bone healing process have remained controversial \[[@r2], [@r5], [@r6]\], because detrimental effects of NSAIDs on fracture healing are premised on the fact that one of the most consistent anabolic effect of PGE~2~ in osteogenesis is to promote differentiation of osteoblasts \[[@r7], [@r30]\].

Synthesis of PGE~2~ is a harmonized process of several enzymes, such as prostaglandin H~2~ synthases, including COX-1 and COX-2, and prostaglandin E synthases, consisting of cytosolic prostaglandin synthase (cPGES), microsomal prostaglandin synthase (mPGES)-1 and mPGES-2. In general, the constitutively expressing enzyme, COX-1 is ubiquitous in most of cells for maintaining homeostasis, but COX-2 is an inducible enzyme that can be upregulated by various proinflammatory stimuli \[[@r35]\]. Downstream of COX enzymes, cPGES is also constitutively expressed and mainly coupled with the COX-1 enzyme \[[@r34]\]. In contrast, mPGES-1 is induced coordinately with the COX-2 enzyme, and it has a preference for COX-2 over COX-1 \[[@r21]\]. mPGES-2 can couple with either of the COX enzymes and is readily detected as COX-1 and cPGES, suggesting it is also a constitutive enzyme for maintenance of cell homeostasis \[[@r20]\].

Animal studies performed with COX-2 knockout mice revealed that the activity of the COX-2 enzyme has an important role in osteogenesis \[[@r32], [@r40]\]. Fracture sites in wild-type animals showed delayed bone healing when they were treated with COX-2 inhibitors for a very long time with a high dose \[[@r8], [@r11], [@r23], [@r32], [@r33]\]. Although these data could explain that PGE~2~ is an essential molecule in fracture healing, the question still remains concerning why there is no clear evidence for delayed fracture healing as a result of COX-2 inhibitor treatment in clinical use. Furthermore, use of NSAIDs would be beneficial in some cases of bone healing, because biology of osteoblasts is likely to be negatively derived when PGE~2~ exceeds certain levels \[[@r26]\]; that is, overflow of PGE~2~ needs to be controlled in chronic inflammatory disease, such as rheumatoid arthritis \[[@r27]\].

An experimental study using fibroblasts from wild-type or COX knockout mice demonstrated overproduction of PGE~2~ by upregulated counterpart COX enzymes in COX-1- or COX-2-deficient cells when compared with intact cells \[[@r15]\]. Bone is one of the few organs that can be fully repaired under the best osteogenic milieu \[[@r31]\]. Based on these findings, it was hypothesized that differentiation of osteogenic cells can be maintained under NSAID treatment by utilizing other channels for PGE~2~ synthesis to restore the level of PGE~2~ during shortages caused by the differences in selectivity of COX-1/COX-2 in each type of NSAID. The purpose of this study was to confirm the cellular responses to NSAIDs, such as carprofen, meloxicam, indomethacin and robenacoxib, during differentiation into osteoblasts from canine bone marrow-derived mesenchymal stem cells (BMSCs).

MATERIALS AND METHODS {#s1}
=====================

*Collection and culture of canine BMSCs*: All experimental protocols were reviewed and approved by the Animal Care and Use Committee of Hokkaido University. Canine bone marrow cells were harvested from the proximal humeri of three 1-year-old female beagle dogs. Approximately 2 m*l* of bone marrow was aspirated into a heparinized syringe and was immediately suspended in Dulbecco's Modified Eagle Medium (DMEM; GIBCO, Grand Island, NY, U.S.A.). The cells in the medium were promptly centrifuged at 800 × *g* for 20 min. Mononuclear cell layers were transferred into a plastic culture dish (100 mm × 20 mm 430167, Corning Inc., Corning, NY, U.S.A.) containing DMEM (GIBCO) with 10% heat-inactivated fetal bovine serum (FBS) and maintained in an incubator at 37°C with a humidified 5% CO~2~ atmosphere. From the day when outgrowing cell colonies were observed, the medium was replaced every 3 days with elimination of the non-adherent cell fraction until adherent cells proliferate and became sub-confluent, which usually took about 10 days. Cells from the second passage were used in this experiment.

*Cell viability assay*: Carprofen (LKT Laboratories, Inc., St. Paul, MN, U.S.A.), meloxicam (Wako, Pure Chemical Industries, Osaka, Japan), indomethacin (Wako) and robenacoxib (Novartis Animal Health US, Inc., Greensboro, NC, U.S.A.) were prepared with different concentrations to achieve final concentrations of 0.01, 0.1, 1, 10 and 100 *µ*M in culture medium. Canine BMSCs were placed at a density of 5 × 10^3^ cells in each well of a 96-well plate (Costar 3595, Corning Inc.) with 100 *µl* culture medium. After 24 hr of incubation for cell adaptation to the culture conditions, each concentration of drugs was treated for 48 hr of the exponential growth phase. Cell viability was determined by a colorimetric assay based on the conversion of 3-(4,5-dimethyl-2-thiazol) 2,5-diphenyl-2H-tetrazolium bromide (MTT; Wako) to a formazan pigment by mitochondrial enzymes in surviving cells during a 4-hr of incubation period \[[@r19]\]. Colorimetric measurement was performed using a microplate photometer (Multiskan FC, Thermo Fisher Scientific Inc., Waltham, MA, U.S.A.) at 570 nm. All samples were evaluated in triplicate.

*Establishment of inflammatory condition*: The optimal concentration of recombinant human interleukin-1β (rhIL-1β, Wako) to trigger mRNA expression of inflammatory enzymes for PGE~2~ synthesis, such as COX-2 and mPGES-1, was confirmed. Briefly, after canine BMSCs were cultured under serum-free conditions for 24 hr, 0.1, 1 and 10 *µ*M of rhIL-1β were supplemented into the medium. Gene expressions were analyzed at 2 hr after each rhIL-1β stimulus using quantitative real-time polymerase chain reaction (qRT-PCR) as described in the section concerning analysis of gene expression.

*Induction of osteogenic differentiation*: Osteogenic differentiation was performed using canine BMSCs at the second passage. As a negative control, canine BMSCs were cultured in basal medium, DMEM, and as a positive control, osteogenic differentiation of the cells was induced by using conventional osteogenic medium, DMEM containing 0.1 *µ*M dexamethasone (Sigma, St. Louis, MO, U.S.A.), 10 mM β-glycerophosphate (Sigma) and 50 mg/m*l* L-ascorbic acid (Wako). To observe effects of NSAIDs on the colony formation of alkaline phosphatase (ALP) positive cells, canine BMSCs were seeded in a multiple micro-mass manner at a density of 2 × 10^4^ cells per a drop of 5 *µl* basal medium in 12-well, flat-bottomed culture plates (Costar 3513, Corning Inc.). After the cells adhered to the plate, the media were changed every other day with or without NSAIDs for 20 days.

*Quantification of PGE~2~ synthesis*: The level of endogenous PGE~2~ in culture supernatant was measured using a Prostaglandin E2 Parameter Assay Kit (R&D Systems, Minneapolis, MN, U.S.A.) according to the instructions of manufacturer. Briefly, after the cells were cultured in serum-free medium for 24 hr, PGE~2~ production was measured at 0, 24 and 48 hr under inflammatory conditions with 1 *n*g/m*l* of rhIL-1β. Effects of NSAIDs on PGE~2~ synthesis were evaluated by supplementation with 10 *µ*M of carprofen, meloxicam, indomethacin or robenacoxib.

*Analysis of gene expression*: Extraction of total cellular RNA was performed by disruption of cultured BMSCs with TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA, U.S.A.). Total RNA was precipitated by centrifugation (15,000 g, 20 min, 4°C) of aqueous phase with isopropanol. Pellets were washed with 70% ethanol and dissolved in 0.1% v/v diethyl pyrocarbonate (DEPC)-treated water after drying in room air. The revers-transcription reaction performed using Moloney Murine Leukemia Virus Teverse Transcriptase (M-MLV RT; Invitrogen). The levels of gene expression were detected by using qRT-PCR in Rotor-Gene Q thermal cycler, (Qiagen, Hilden, Germany) with KAPA SYBR FAST qPCR Master Mix (KAPA Biosystems, Boston, MA, U.S.A.). The acquired data were analyzed by normalization to GAPDH as an internal control. All sequences of primers used in this experiment are listed in [Table 1](#tbl_001){ref-type="table"}Table 1.Sequences of primers used for real-time PCRGenePrimer sequence (5′ to 3′)Product size (bp)*COX-1*(Forward) GGC AGT TCA GAA TGT TGT GC162(Reverse) GCA ATG CAC TCT GGT TAG GC*COX-2*(Forward) GCG AGG AAC CAA CAG CTT AC171(Reverse) TGA CAC GGG TTA CGT CAT GT*cPGES*(Forward) AAA AGG TGA ATC TGG CCA GTC ATG G172(Reverse) ATC CTC ATC ACC ACC CAT GTT GTT C*mPGES-1*(Forward) ACT GGC CAT GAG CCG CTG TG104(Reverse) TCC TGT GTT CAG CAC GCT GCC*EP2*(Forward) AAA TGG GAC CTC CAA GCT CT124(Reverse) ATG AAA CCC GAC AAC AGA GG*EP4*(Forward) GTG TTT GGC TGT GCT CAG AA110(Reverse) CAT GGG TTC CCG TAT GAA TC*ALP*(Forward) CCA AGC TCA ACA GAC CCT GA102(Reverse) GAG ACA CCC ATC CCA TCT CC*Osteocalcin*(Forward) AGG AAG CTT ACC AGC GCT TC138(Reverse) TGA CAA GGA CCC CAC ACT TG*GAPDH*(Forward) CTG AAC GGG AAG CTC ACT GG129(Reverse) CGA TGC CTG CTT CAC TAC CT.

*Intracellular ALP activity*: Cell layers were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed in 10 mM Tris-HCl solution (pH 7.4) containing 0.05% (v/v) Triton X-100 (ICN Biomedicals Inc., Aurora, OH, U.S.A.). After vigorous shaking and 30 min of sonication, supernatants of the cell lysates were separated by centrifugation at 20,000 × *g* for 30 min and were stored at −80°C until analysis. To access ALP activity of the cells, samples were thawed and reacted with *P*-nitrophenyl phosphate (Sigma) for 10 min at 37°C in substrate solution (pH 10.5), which contained 1 mg/m*l P*-nitrophenyl phosphate, 100 mM glycine, 1 mM MgCl~2~ and 1 mM ZnCl~2~. The released *P*-nitrophenol was measured by using a microplate photometer (Multiskan FC, Thermo Fisher Scientific Inc.) at 405 nm and normalized using the total protein concentration measured by the modified Bradford method (Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A.) \[[@r3]\]. The ALP activity was expressed as *µ*mol/min/mg protein.

*Quantification of osteocalcin production*: Osteocalcin secreted by mature osteoblasts was evaluated using an Intact Human Osteocalcin EIA Kit (Biomedical Technologies Inc., Stoughton, MA, U.S.A.) according to the manufacturer's instructions. Culture supernatants were collected during medium change and were stored at −80°C until the day they were quantified.

*Quantification of extracellular calcium deposition*: The amounts of extracellular matrix mineralized during osteoblast differentiation were compared by a colorimetric quantification method using an Alizarin red S (ARS, Sigma)-based assay \[[@r10]\]. Briefly, the cell layer in the well was washed with PBS and fixed in 10% (v/v) formaldehyde at room temperature for 15 min. After washing twice with distilled water, the plate was incubated with 40 *n*M ARS (pH 4.1) per well for 20 min. Unincorporated dye was washed away with distilled water and aspirated. The dye was extracted by detachment of cell layers with 10% (v/v) acetic acid and transferred to a microcentrifuge tube. The slurry was centrifuged at 20,000 × *g* for 15 min after dissolution by heating at 85°C for 10 min. The optical density of the supernatant was read by a microplate photometer (Multiskan FC, Thermo Fisher Scientific Inc.) at a wavelength of 405 *n*m.

*Morphological evaluation*: The early period of differentiation of osteoblasts from canine BMSCs was observed using ALP staining. Briefly, the cells were washed with PBS and fixed with 4% paraformaldehyde for 2 min. After rinsing, the cells were incubated in 0.1 M Tris-HCl buffer (pH 9.3) containing 0.25% (w/v) naphthol-AS-BI-phosphoric acid sodium salt (Sigma) and 0.75% (w/v) fast blue RR salt (Sigma) at 37°C for 30 min.

Calcium deposition in the matrix of differentiated osteoblasts was confirmed using von Kossa staining. Briefly, the cells fixed with 4% paraformaldehyde for 2 min were treated with 2% silver nitrate (Wako) solution and placed under ultraviolet light at room temperature for 1 hr. After rinsing, the cells were bleached in 5% sodium thiosulfate (Wako) for 2 min.

*Statistics*: Data were statistically analyzed by performing the nonparametric Mann-Whitney U *test using* commercial software (SPSS, version 12.0.1, SPSS Inc., Chicago, IL, U.S.A.). All data were expressed as means ± standard deviations (SDs). Values of *p*\<0.05 were considered to be statistically significant.

RESULTS {#s2}
=======

*Doses of NSAIDs inhibiting PGE~2~ synthesis under inflammatory conditions without effects on cell viability*: Effects of NSAIDs on viability of canine BMSCs were assessed quantitatively by MTT assay. Cell culture for 48 hr resulted in no significant effects on cell viability for all NSAIDs at concentrations up to 10 *µ*M ([Fig. 1A--1D](#fig_001){ref-type="fig"}Fig. 1.Effects of carprofen (A), meloxicam (B), indomethacin (C) and robenacoxib (D) on viability and PGE~2~ synthesis in canine bone marrow-derived mesenchymal stem cells. Cell viability was determined using MTT assay after drug treatment for 48 hr. Production of PGE~2~ (C) was quantified by ELISA after 24 hr of cell culture with 0.1, 1 and 10 *µ*M of NSAIDs. Data are means ± SD from three independent experiments that were performed in triplicate. \* *p*\<0.05.). The optimal concentrations of rhIL-1β to induce enzymes responsible for inflammatory PGE~2~ synthesis were assessed by confirmation of the expression of genes, such as COX-2 and mPGES-1. At 2 hr after stimulation with 0.1, 1 and 10 *n*g/m*l* of rhIL-1β, the expression levels of COX-1 and COX-2 mRNA were increased ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Effects of recombinant human interleukin-1β (rhIL-1β) on mRNA expression of enzymes for PGE~2~ synthesis. Canine bone marrow-derived mesenchymal stem cells were stimulated with each concentration of rhIL-1β (0.1, 1 and 10 *n*g/m*l*) after 24 hr of incubation in serum-free medium. Gene expression at 2 hr was analyzed using quantitative real-time polymerase chain reaction. Data are means ± SD (n=3). \* *p*\<0.05.). The gene expression of mPGES-1 was increased by 1 and 10 *n*g/m*l* of rhIL-1β, indicating that inflammatory conditions could be triggered by rhIL-1β at concentration ≥ 1 *n*g/m*l*. In the present study, 1 *n*g/m*l* of rhIL-1*β* was supplemented into osteogenic medium to induce the expression of COX-2 and mPGES-1. At 24 hr during cell culture under inflammatory conditions, PGE~2~ synthesis was dose-dependently suppressed by NSAIDs, except for robenacoxib, at concentrations ≤ 10 *µ*M, which were shown to not interfere with cell viability ([Fig. 1A--1D](#fig_001){ref-type="fig"}). The dose for each NSAID in this experiment was 10 *µ*M and was selected to inhibit COX activity.

*Differentiation of osteoblasts from canine BMSCs*: The time-course expression levels of markers for osteoblasts were changed during osteogenic differentiation. The levels of ALP expression fluctuated after the highest expression was observed on day 4. Osteocalcin expression gradually increased after the peak of ALP expression, which was followed by an increase in calcium deposition. Calcification in the cellular matrix reached the maximum level on day 20 ([Fig. 3C](#fig_003){ref-type="fig"}Fig. 3.Differentiation of osteoblasts in canine bone marrow-derived mesenchymal stem cells. Gene expression (A) was analyzed using quantitative real-time polymerase chain reaction. Enzyme activity of ALP (B) was measured by colorimetric assay using *p*-nitrophenylphosphate. Osteocalcin (B) was quantified by ELISA. Level of calcification (C) was quantified by Alizarin red S assay. Morphological analysis (D) was performed using ALP staining and von Kossa staining. Data are means ± SD (n=3).), at which point osteocalcin secretion was detected at its highest level. Differentiation of osteoblasts in canine BMSCs was also supported by morphologic analysis ([Fig. 3D](#fig_003){ref-type="fig"}), including colony formation of ALP-positive cells on day 4 and calcified matrix formation on day 20.

*Expression of osteoblastic markers during NSAID treatment*: Effects of NSAIDs on differentiation of osteoblasts were evaluated based on the expression levels of ALP, osteocalcin and calcification on the day when each osteoblastic marker was expressed at the highest level. On day 4, the expression level of ALP mRNA ([Fig. 4A](#fig_004){ref-type="fig"}Fig. 4.Effects of NSAIDs on differentiation of osteoblasts in canine bone marrow-derived mesenchymal stem cells. Gene expression (A, D) was analyzed using quantitative real-time polymerase chain reaction. Enzyme activity of ALP (B) was measured by colorimetric assay using *p*-nitrophenylphosphate. Morphological analysis (C) was performed using ALP staining. Level of calcification (E) was quantified by Alizarin red S assay on day 20. Expression levels of ALP (A, B and C) were analyzed on day 4. In groups for recovery, 10 nM of PGE~2~ was added (C and E). Car, carprofen (10 *µ*M); Mel: meloxicam (10 *µ*M); Ind, indomethacin (10 *µ*M); Rob, robenacoxib (10 *µ*M). Data are means ± SD (n=3). \* *p*\<0.05; † *p*\<0.05 between 2 columns.), ALP activity ([Fig. 4B](#fig_004){ref-type="fig"}) and colony formation of ALP-positive cells ([Fig. 4C](#fig_004){ref-type="fig"}) were decreased by all the NSAIDs. Suppressed differentiation of ALP-positive cells by NSAIDs was restored by supplementation of PGE~2~ ([Fig. 4C](#fig_004){ref-type="fig"}). The expression level of osteocalcin mRNA showed no decrease due to treatment with NSAIDs on day 20 ([Fig. 4D](#fig_004){ref-type="fig"}). Synthesis of protein of osteocalcin also showed no significant difference between the control and groups receiving NSAID treatment (data not shown). The level of calcification was decreased by NSAIDs on day 20, which was restored by continuous supplementation with PGE~2~ ([Fig. 4E](#fig_004){ref-type="fig"}).

*Expressions of PGE~2~-related genes and synthesis of PGE~2~ under NSAIDs treatment*: Continuous treatment with NSAIDs induced upregulation of genes for PGE~2~-related receptors ([Fig. 5A](#fig_005){ref-type="fig"}Fig. 5.Compensatory response under NSAID treatment during osteoblast differentiation in canine bone marrow-derived mesenchymal stem cells. Gene expression was analyzed on day 4 using quantitative real-time polymerase chain reaction (A and B). Production of PGE~2~ (C) was quantified by ELISA. Car, carprofen (10 *µ*M); Mel, meloxicam (10 *µ*M); Ind, indomethacin (10 *µ*M); Rob, robenacoxib (10 *µ*M). Data are means ± SD (n=3). \* *p*\<0.05.) and enzymes ([Fig. 5B](#fig_005){ref-type="fig"}). Gene expression levels of PGE~2~ receptors, such as EP2 and EP4, were upregulated on day 4 by NSAIDs, except in the case of meloxicam and indomethacin for EP2 mRNA expression. Expression of COX-2 mRNA was also upregulated by NSAIDs on day 4 and was more increased by carprofen, about 4-fold, than by the other NSAIDs. The rates of PGE~2~ synthesis were suppressed for 24 hr by NSAIDs ([Fig. 5C](#fig_005){ref-type="fig"}) and were negatively correlated with the upregulated expression patterns of COX-2 mRNA. Suppressed PGE~2~ synthesis was restored in each group at 48 hr, at which time the amount of PGE~2~ synthesized was about 2-fold higher in robenacoxib group than in other groups.

DISCUSSION {#s3}
==========

In the present study, canine BMSCs differentiated into osteoblasts under inflammatory conditions of COX-2-induced PGE~2~ synthesis. Serial changes in the expressions of osteoblastic markers during the differentiation were confirmed by upregulation of ALP activity in pre-osteoblasts, followed by an increase of osteocalcin synthesis in mature osteoblasts and by calcification of matrix, which was previously shown to be correlated with osteoblastic differentiation of mesenchymal stem cells in humans \[[@r16]\] and rats \[[@r22]\]. After the peak of ALP expression, the cells accumulated to form nodules, which were the core for starting of calcified matrix formation. Then, in the vacant space around the nodules, the cells continuously proliferated and formed new nodules after the second peak of ALP expression. This is why two peaks of ALP and osteocalcin expression can be observed with the same patterns in [Fig. 3A](#fig_003){ref-type="fig"}.

Continuous treatment of NSAIDs partially suppressed the osteogenic process in canine BMSCs, such as ALP expression and calcification. While expression of ALP was decreased by NSAIDs at its peak, the level of expression was still close to that of the control on day 4 ([Fig. 4A and 4B](#fig_004){ref-type="fig"}) and could have gradually increased with differentiation into mature osteoblasts, resulting in unsuppressed expression of osteoclacin on day 20. Expression of osteocalcin mRNA decreased by NSAIDs during differentiation of osteoblasts in human BMSCs on day 4 \[[@r38]\]. However, we detected uninhibited expression of mRNA and protein production of osteocalcin when its expression was maximal, suggesting that NSAIDs would only temporarily suppress expression of osteocalcin. The level of calcification on day 20 was somewhat suppressed, which would be related to delayed ALP expression due to insufficiency of PGE~2~ synthesis. It is important to note that the deficiency in PGE~2~ in the osteogenic milieu under treatment with NSAIDs could be reversed by the osteogenic cells, leading to prevention of markedly derailed osteoblast differentiation.

Inhibitory effects of NSAIDs on PGE~2~ synthesis in canine BMSCs are caused by partial blockage of the COX-1 or COX-2 pathway, depending on the selectivity of the drugs for COXs. Expressions of genes for inflammatory PGE~2~ synthesis, such as COX-2 and mPGES-1 mRNA, were induced by 1 *n*g/m*l* of rhIL-1β, which was also shown to be the concentration that stimulates synthesis of protein of COX-2 in human BMSCs \[[@r38]\]. Under this condition, carprofen, meloxicam and indomethacin showed significant suppression of PGE~2~ synthesis at 24 hr, supporting the expected pharmacological inhibitory effects on inflammatory PGE~2~ synthesis. However, restoration of the level of PGE~2~ during shortage was observed in every NSAID group at 48 hr, indicating that there would be some intrinsic mechanisms to correct shortages of PGE~2~ in canine BMSCs.

Upregulated expressions of receptors for PGE~2~, such as EP2 and EP4, could be an effective way to increase sensitivity to PGE~2~. It has been demonstrated that endogenous PGE~2~ could induce COX-2 expression via a PG-mediated auto-amplification loop by stimulating EP2 and EP4 in osteoblasts \[[@r24], [@r29]\]. These results imply that increased expression of EP2 or EP4 acts not only as a part of the corrective mechanism for PGE~2~ shortage but also as an enhancer for osteogenic differentiation. Furthermore, EP2 and EP4 have been implicated in the bone anabolic effect of PGE~2~ \[[@r1], [@r18], [@r25]\]. A study performed with selective agonists for PGE~2~ receptors and cells cultured from COX-2 knockout mice demonstrated that signaling via EP4 was more likely to play an important role in fracture repair than that via EP2 \[[@r37]\]. It is probable that increased expression of EP4 contributes to the upregulated expression of osteocalcin mRNA during indomethacin treatment ([Fig. 4D](#fig_004){ref-type="fig"}).

Significantly increased expression of COX-2 mRNA was also detected and was negatively correlated with suppression of PGE~2~ synthesis. Furthermore, expression of COX-1 mRNA was upregulated by robenacoxib, while it is generally known to express continuously. The rapid rate of restoration via the upregulated COX-1 channel would be the reason why synthesis of PGE~2~ was not suppressed at 24 hr of treatment with robenacoxib. Robenacoxib may have a relatively wider safety margin due to fast recovery of PGE~2~ after treatment, while it has been reported as a COX-2 selective inhibitor \[[@r13]\]. These results indicate that both COX-1 and COX-2 could be induced by PGE~2~ shortage to play physiological roles in compensation of PGE~2~ in canine BMSCs. Therefore, differentiation of osteoblasts would be partially affected by NSAIDs, depending on the net level of PGE~2~ that would be maintained by compensatory upregulation of COX-1/COX-2 with or without EP2/EP4, while the efficiency of synthesis of PGE~2~ is further affected by COX-2 than by COX-1 \[[@r15]\].

Suppressive effects of NSAIDs on osteogenesis would be minimal in clinical short-term use for analgesic purposes. The maximum plasma concentrations of carprofen \[[@r17]\], meloxicam \[[@r39]\], indomethacin \[[@r12]\] and robenacoxib \[[@r13]\] in dogs have been determined in kinetic studies: 76.29 *µ*M (20.60 *µ*g/m*l* at 4.00 mg/kg/dose s.c.), 2.09 *µ*M (0.78 *µ*g/ m*l* at 0.20 mg/kg/dose s.c.), 58.38 *µ*M (20.9 ± 4.5 *µ*g/m*l* at 10.00 mg/kg/dose p.o.) and 2.01 *µ*M (0.66 *µ*g/m*l* at 1.00 mg/kg/dose s.c.), respectively. These studies indicate that the doses of meloxicam and robenacoxib used in this experiment were over their maximum plasma concentrations, but that of carprofen was not. Because analgesic effects of NSAIDs are attained not only by peripheral inhibition of synthesis of PGE~2~ but also by an increase in the threshold in nociceptive neurons at the central site \[[@r4]\] and the concentration of NSAIDs in peripheral tissue is lower than in plasma concentration \[[@r9]\], analgesic doses of NSAIDs would hardly affect osteogenic differentiation at the site of fracture. However, fracture patients who need analgesic treatment with NSAIDs for a longer-term are recommended to be prescribed with NSAIDs that offer a more secure compensatory response to shortage of PGE~2~ in osteogenic cells, since long-term treatment with some NSAIDs has been shown to have effects that minimize heterotopic bone formation after arthroplasty \[[@r36]\].

In conclusion, canine BMSCs have a compensatory mechanism for NSAIDs, which appears to be a reversible switch that regulates the level of PGE~2~ for maintenance of osteogenesis. These data could be used to explain the discrepancy between the suppressive effect of NSAIDs on osteogenesis *in vitro* and the rarely reported deterioration of bone healing during clinical use of NSAIDs as pain-killers.
